Finally, in order to evaluate the influence of BACE1 in serum on disease onset and progression, we generated Kaplan-Meier survival curves depicting age at onset (in AD patients) or age at clinical conversion (in MCI-AD) stratified on the basis of their BACE1 activity in serum. Here, BACE1 is linked to Alzheimer disease.